Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-01-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
天健会计师事务所（特殊普通合伙）关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件的审核问询函中有关财务事项的说明（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed financial and operational disclosure related to a company's application for issuing convertible bonds to unspecified investors. It includes extensive financial data, investment project details, cost breakdowns, and financial projections. The presence of detailed financial figures, investment scale, and financial analysis indicates this is a comprehensive financial report rather than a brief announcement or certification. The document references a regulatory inquiry from the Shanghai Stock Exchange and includes responses to financial questions, which aligns with a formal filing related to financing activities. Given the focus on financing scale, investment projects, and financial benefits, this document fits best under the category of Capital/Financing Update (CAP).
2024-01-12 Chinese
奥锐特药业股份有限公司关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (562 characters) about a subsidiary company receiving a High-Tech Enterprise Certificate, issued by government authorities. It includes no financial data, no report attachments, and no mention of financial results or management changes. It is a regulatory announcement about a certification and its impact on tax treatment, not a financial report or detailed management disclosure. The document is not a report itself but an official announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-11 Chinese
奥锐特药业股份有限公司2024年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2024 First Extraordinary General Meeting" of 奥锐特药业股份有限公司. It contains detailed agenda items, meeting procedures, voting instructions, and multiple proposals for shareholder approval, including amendments to the company charter and governance systems, and extensions of authorizations related to convertible bond issuance. The content is clearly related to the materials provided for a shareholders' meeting, not the results of voting or a summary announcement. The document length is 8689 characters, which is substantial and contains detailed meeting materials rather than a brief announcement. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2024-01-11 Chinese
奥锐特药业股份有限公司关于收到上海证券交易所《关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券的审核中心意见落实函》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding receiving a regulatory letter from the Shanghai Stock Exchange about the review of the company's application to issue convertible bonds to unspecified investors. It mentions the need to submit further documents and that the issuance is subject to regulatory approval. The document is short (634 characters) and serves as a regulatory update on the financing process, not the actual financing report or prospectus. Therefore, it fits best under Capital/Financing Update (CAP).
2024-01-08 Chinese
奥锐特药业股份有限公司关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会) for 奥锐特药业股份有限公司. It includes details about the meeting date, voting methods, agenda items to be discussed, registration procedures, and proxy authorization forms. There are no financial statements, earnings data, or detailed management analysis. The document is an announcement informing shareholders about the meeting logistics and agenda, not the actual voting results or meeting minutes. It is also not a proxy solicitation or remuneration report. Given the content and length (3570 characters), it fits the category of a shareholder meeting notice, which corresponds to AGM Information (AGM-R).
2024-01-02 Chinese
奥锐特药业股份有限公司独立董事关于第三届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the fifth meeting of the third board of directors of 奥锐特药业股份有限公司. It includes opinions on external guarantee limits, forward foreign exchange transactions, and extension of validity periods for convertible bond issuance resolutions and related authorizations. The content focuses on board meeting decisions and independent directors' assessments rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor a call transcript or earnings release. The document is a formal board/management related announcement concerning governance and board decisions, fitting the Board/Management Information (MANG) category.
2024-01-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.